Breast cancer is the most diagnosed cancer among women in the U.S.* In 2023, there will be an estimated 297,790 new cases of invasive breast cancer in women, 2,800 new cases in men, and an additional 55,720 cases of ductal carcinoma in situ (DCIS)** in women.***

**The National Breast Cancer Coalition (NBCC) is a grassroots organization dedicated to ending breast cancer through action and advocacy.

**INCIDENCE**
Breast cancer is the most diagnosed cancer among women in the U.S.* In 2023, there will be an estimated 297,790 new cases of invasive breast cancer in women, 2,800 new cases in men, and an additional 55,720 cases of ductal carcinoma in situ (DCIS)** in women.***

**Lifetime Risk**
For women in the U.S., the lifetime risk of being diagnosed with invasive breast cancer has increased since 1975.2,3

<table>
<thead>
<tr>
<th>Year</th>
<th>Incidence</th>
<th>Probability</th>
<th>Risk</th>
</tr>
</thead>
<tbody>
<tr>
<td>2017-2019</td>
<td>1 in 8</td>
<td>12.9%</td>
<td></td>
</tr>
<tr>
<td>1975-1977</td>
<td>1 in 11</td>
<td>9.1%</td>
<td></td>
</tr>
</tbody>
</table>

**Incidence By Age**
Older women are more likely to get invasive breast cancer than younger women. From 2015-2019, the median age of a breast cancer diagnosis was 62 years.2

---

*Excluding basal cell and squamous cell skin cancers, which are not required to be reported to cancer registries, and carcinomas in situ.

**Annual incidence counts of lobular carcinoma in situ are no longer measured following its removal from the 2017 edition of the AJCC breast cancer staging program.

***These statistics do not account for the effect of the COVID-19 pandemic.
Breast cancer is the 2nd leading cause of cancer deaths for women in the United States, after lung cancer. In 2023, it is estimated that 43,170 women and 530 men will die of breast cancer.¹

Progress in reducing breast cancer mortality has slowed in recent years, from 2% to 3% annually during the 1990s and 2000s to 1% annually from 2011 to 2020.² While the breast cancer mortality rate has declined, the number of women and men who die each year is rising and will continue to rise as the aging population grows.

**Mortality By Age**
From 2016-2020, the median age at death from breast cancer was 70 years of age.⁵

Every 13 minutes, a woman dies from breast cancer.

*Racial Disparities*

Despite a similar incidence, mortality from breast cancer among Black women is 40% higher compared with White women.¹²

**Incidence & Mortality Rates**

<table>
<thead>
<tr>
<th>Incidence Rate Per 100,000 by Race/Ethnicity (2015-2020)</th>
<th>Mortality Rate Per 100,000 by Race/Ethnicity (2015-2020)</th>
</tr>
</thead>
<tbody>
<tr>
<td>White: 133.7</td>
<td>White: 19.7</td>
</tr>
<tr>
<td>Black: 127.8</td>
<td>Black: 27.6</td>
</tr>
<tr>
<td>American Indian / Alaska Native: 111.3</td>
<td>American Indian / Alaska Native: 20.5</td>
</tr>
<tr>
<td>Asian American / Pacific Islander: 101.3</td>
<td>Asian American / Pacific Islander: 11.7</td>
</tr>
<tr>
<td>Hispanic/Latino: 99.2</td>
<td>Hispanic/Latino: 13.7</td>
</tr>
</tbody>
</table>

*These statistics are based on 2020 mortality data and account for the first year only of the COVID-19 pandemic.
The risk of local and distant (metastatic) recurrence varies greatly based on many factors. Estimates of long-term cumulative risk range from about 5% to 60%, with most falling between 10%-30%. Furthermore, recurrence risk remains elevated more than 3 decades from the primary diagnosis.

**Prevalence**

As of January 2022, there were an estimated >4 million women living with a history of invasive breast cancer in the U.S.

It is estimated that in 2018, 140,230 women in the U.S. were living with metastatic breast cancer. By 2025, this number is expected to increase to 169,347.

**Risk Factors**

Only 5-10% of breast cancers are hereditary. The strongest risks for breast cancer are age and being assigned female at birth.

Other non-modifiable risk factors include:
- Genetic mutations, such as in BRCA1 and BRCA2
- Starting menstrual periods before age 12 and menopause after age 55
- Having dense breasts
- Personal history of breast cancer or benign breast diseases
- Family history of breast cancer
- Previous radiation therapy in chest or breasts
- Exposure to the drug diethylstilbestrol (DES)
- Naturally high levels of estrogen or testosterone

Risk factors that are potentially modifiable include:
- Lack of physical activity
- Being overweight or having obesity (post-menopause)
- Taking hormonal medications, such as menopausal hormone therapy or hormonal contraceptives
- Reproductive history, including being over 30 years of age at first full-term pregnancy, not breastfeeding, and never having a full-term pregnancy
- Alcohol consumption

**DCIS & Screening**

The diagnosis of ductal carcinoma in situ (DCIS) was rare before 1980, but the widespread adoption of screening mammography led to a massive increase in DCIS diagnosis. From 1980-2000, women aged 20-49 experienced a 400% increase in DCIS diagnoses, and women over the age of 50 experienced over a 900% increase in DCIS diagnoses. However, screening has not decreased the rate of lethal disease (i.e., distant stage) at diagnosis.

Overdiagnosis of breast cancer (i.e., cancer that would never have become a problem) by screening mammography is difficult to determine, with the most credible estimates ranging from 11%-22%. False positive and false negative mammography results are also possible. Over a 10-year period, more than half of women getting an annual mammogram will receive a false-positive result.
The current methods of treatment in use in the U.S.

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Surgery</td>
<td>Mastectomy &amp; Lumpectomy</td>
</tr>
<tr>
<td>Chemotherapy</td>
<td>Radiation</td>
</tr>
<tr>
<td>Hormonal Therapy</td>
<td>Immunotherapy</td>
</tr>
<tr>
<td>Targeted Therapy</td>
<td></td>
</tr>
</tbody>
</table>

NBCC acknowledges that breast cancer impacts people of all gender identities.

REFERENCES